================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
JUNE 30, 2009
ALLIANCE PHARMACEUTICAL CORP.
(Exact name of registrant as specified in its charter)
NEW YORK 000-12950 14-1644018
(State or other jurisdiction of (Commission File No.) (IRS Employer
incorporation) Identification No.)
7590 FAY AVENUE, SUITE 404
LA JOLLA, CALIFORNIA 92037
(Address of principal executive offices)
(858) 779-1458
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02. RESULTS OF OPERATION AND FINANCIAL CONDITION.
Alliance Pharmaceutical Corp (the "Company") has been unable to obtain
an audit of the annual financial statements contained in the attached Exhibit
99.1 by an independent registered accounting firm using professional auditing
standards and procedures, although such an audit is required by Form 10-K
pursuant to Rule 10-01(d) of Regulation S-X. Currently, the Company does not
have the funds to pay an independent registered accounting firm to audit the
annual financial statements and, therefore, is unable to file a Form 10-K for
the year ended June 30, 2009 as required by applicable SEC rules. As a result,
the Company has furnished the information that would otherwise be filed in its
Form 10-K in Exhibit 99.1 attached hereto in order to disclose information about
the Company's financial state of affairs in a timely fashion.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS
Exhibit No. Description
- ----------- -----------
99.1 Report of Alliance Pharmaceutical Corp. for the fiscal year ended June
30, 2009.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALLIANCE PHARMACEUTICAL CORP.
Date: October 20, 2009 /s/ Duane J. Roth
---------------------------------
Duane J. Roth
Chief Executive Officer
2